<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02685189</url>
  </required_header>
  <id_info>
    <org_study_id>64,185-06LT-2</org_study_id>
    <nct_id>NCT02685189</nct_id>
  </id_info>
  <brief_title>Long-Term Clinical Follow-Up of Children Enrolled in Stannsoporfin Clinical Trial Protocol No. 64,185-06-2(W)</brief_title>
  <official_title>Long-Term Clinical Follow-Up of Children Enrolled in Stannsoporfin Clinical Trial Protocol No. 64,185-06-2(W)(WS)(ISNHP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to provide a mechanism to collect Long Term Clinical Data
      from those babies who participated in the primary Study 64,185-06-2(W)(WS)(ISNHP) &quot;An
      Open-Label Study Of The Safety And Clinical Pharmacology Of Stanate速 In Infants At-Risk For
      Exchange Transfusion&quot;.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this protocol is to provide a mechanism to collect Clinical Data from those
      babies who participated in the primary Study 64,185-06-2(W)(WS)(ISNHP) &quot;An Open-Label Study
      Of The Safety And Clinical Pharmacology Of Stanate速 In Infants At-Risk For Exchange
      Transfusion&quot;. Data on long-term impact of Stannsoporfin on the physical, neurological,
      neurodevelopmental, biochemical, metabolic and hematopoietic profiles of the children will be
      collected at 9 and 18 months, 3, 6 and 9 years after Stannsoporfin administration
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study stopped for business reasons and not for any safety reasons.
  </why_stopped>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">May 10, 2016</completion_date>
  <primary_completion_date type="Actual">May 10, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>NEUROLOGICAL EXAMINATION; Child Behavior Check List</measure>
    <time_frame>10 years</time_frame>
    <description>Child Behavior Check List is a standardized measure in child psychology for evaluating maladaptive behavioral and emotional problems in preschool patients</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Hyperbilirubinemia</condition>
  <arm_group>
    <arm_group_label>0.75 mg/kg Previous exposure to stannsoporfin</arm_group_label>
    <description>Previous exposure 0.75 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5 mg/kg Previous exposure to stannsoporfin</arm_group_label>
    <description>Previous exposure 1.5 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Previous exposure to stannsoporfin</intervention_name>
    <description>No intervention in this protocol</description>
    <arm_group_label>0.75 mg/kg Previous exposure to stannsoporfin</arm_group_label>
    <arm_group_label>1.5 mg/kg Previous exposure to stannsoporfin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All children who have been enrolled and received Stanate速 Injection/Placebo in Study
        Protocol 64,185-06-2(W)(WS)(ISNHP) are eligible for this follow-up.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All children who have been enrolled and received Stanate速 Injection/Placebo in Study
             Protocol 64,185-06-2(W)(WS)(ISNHP) are eligible for this follow-up.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Ruiz, MD</last_name>
    <role>Study Director</role>
    <affiliation>InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company</affiliation>
  </overall_official>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2016</study_first_posted>
  <last_update_submitted>July 17, 2017</last_update_submitted>
  <last_update_submitted_qc>July 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperbilirubinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tin mesoporphyrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

